Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

van Besien K et al. – The observation of MDC after alemtuzumab conditioning does not by itself constitute a risk factor for relapse and should not be used to guide therapeutic intervention. By contrast, declining donor chimerism between Day 30 and Day 180 is associated with a somewhat increased risk of disease recurrence. The high incidence of MDC after alemtuzumab containing conditioning contributes to the low risk of acute and chronic GVHD.

Related Articles

Effects of Lipopolysaccharide on the Induction of Mixed Chimerism in Cyclophosphamide-Induced Tolerance
Scandinavian Journal of Immunology, 11/04/09    Relevance Score: 66%

Are CD4+CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?
Arthritis Research & Therapy, 10/14/09    Relevance Score: 48%

FoxP3+ Regulatory T Cells Restrain Splenic Extramedullary Myelopoiesis via Suppression of Hemopoietic Cytokine-Producing T Cells
Journal of Immunology, 11/10/09    Relevance Score: 46%

CD4+ T Cells and Lactobacillus casei Control Relapsing Colitis Mediated by CD8+ T Cells
Journal of Immunology, 10/22/09    Relevance Score: 46%

Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis
International Immunology, 10/14/09    Relevance Score: 46%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address